CUSIP: 185860202
Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
1,067,304
-
Share change
-
+444,594
-
Total reported value
-
$5,601,575
-
Price per share
-
$5.25
-
Number of holders
-
16
-
Value change
-
+$2,988,918
-
Number of buys
-
10
-
Number of sells
-
6
Quarterly Holders Quick Answers
What is CUSIP 185860202?
CUSIP 185860202 identifies CBLI - CLEVELAND BIOLABS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2021
-
Previous quarter:
Q4 2020
Recent filing periods for CUSIP 185860202:
Institutional Holders of CLEVELAND BIOLABS INC - COM NEW (CBLI) as of Q1 2021
As of 31 Mar 2021,
CLEVELAND BIOLABS INC - COM NEW (CBLI) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,067,304 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, ARS Investment Partners, LLC, CITADEL ADVISORS LLC, Cambridge Investment Research Advisors, Inc., NORTHERN TRUST CORP, and ROYAL BANK OF CANADA.
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.